Automate Your Wheel Strategy on GSK
With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GSK
- Rev/Share 7.7277
- Book/Share 3.3466
- PB 4.3054
- Debt/Equity 0.0
- CurrentRatio 0.8682
- ROIC 0.1098
- MktCap 60579014639.616
- FreeCF/Share 0.8929
- PFCF 16.6289
- PE 19.3314
- Debt/Assets 0.0
- DivYield 0.0396
- ROE 0.2244
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | GSK | Berenberg | Buy | Hold | -- | -- | June 3, 2025 |
| Initiation | GSK | Exane BNP Paribas | -- | Neutral | -- | $35.25 | April 15, 2025 |
| Initiation | GSK | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
News
Here's Why GSK (GSK) is a Strong Momentum Stock
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.
Read More
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
Published: June 16, 2025 by: Business Wire
Sentiment: Neutral
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). “Too many people living with lupus face delays in diagnosis and disconnects in care,” said Court Horncastle, Senior Vice President at GSK. “With this initiative, we're proud to support the organizations working within local communities to improve.
Read More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Published: June 09, 2025 by: Benzinga
Sentiment: Positive
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Read More
Here's Why GSK (GSK) is a Strong Value Stock
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.
Read More
Dow Jones Industrial Average (DIA) Live June 3: OECD Cuts US GDP Forecast, DIA Dives
Published: June 03, 2025 by: 24/7 Wall Street
Sentiment: Negative
The OECD lowered US GDP forecasts for 2025 and 2026 today. Meta and Constellation are teaming up in a nuclear power supply agreement that will last 20 years.
Read More
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved $225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022 , and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billion First outcome from Strategic Review Committee's ongoing efforts to maximize …
Read More
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
Read More
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.
Read More
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
Published: May 28, 2025 by: Benzinga
Sentiment: Positive
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy.
Read More
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.
Read More
FDA Approves GSK's Nucala for Expanded Use in COPD
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.
Read More
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. FDA's approval was based on data from the positive MATINEE and METREX phase III trials. Across these trials, mepolizumab showed a clinically meaningful and statistically significant reduction in the annualized rate of moderate/s.
Read More
Why GSK (GSK) is a Top Value Stock for the Long-Term
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space.
Read More
GSK or ACAD: Which Is the Better Value Stock Right Now?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Read More
GSK's Blood-Cancer Treatment Combinations Approved in Japan
Published: May 19, 2025 by: WSJ
Sentiment: Positive
The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.
Read More
Glaxo (GSK) Upgraded to Buy: Here's What You Should Know
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis.
Read More
5 Reasons GSK Looks Good
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Positive
GSK's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Both turnover and EPS growth exceeded expectations, and the company's guidance indicates that the stock's forward P/E is competitive too. Additionally, GSK's medium-to-long-term financial prospects look good too, based on the company's latest outlook, which also works in the stock's favour.
Read More
Here's Why GSK (GSK) is a Strong Growth Stock
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
Read More
GSK plc (GSK) Q1 2025 Earnings Conference Call Transcript
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral
GSK plc (NYSE:GSK ) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ET Company Participants Constantin Fest - Head of IR Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Julie Brown - CFO David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JP Morgan Kerry Holford - Berenberg Jo Walton - UBS Graham Parry - Bank of America Simon Baker - Redburn Rajan Sharma - Goldman Sachs Sarita Kapila - Morgan Stanley Constantin Fest Ladies and gentlemen, a very warm welcome to this GSK Q1 2025 Results …
Read More
Here's Why GSK (GSK) is a Strong Momentum Stock
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | GSK Leads Cervarix Market Amid Global Vaccination Efforts
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc leads the market, with Cervarix targeting HPV-linked conditions like cervical cancer. Advanced HPV vaccines and personalized immunization strategies are emerging trends. The report details market dynamics, historical data, and future growth projections. The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc …
Read More
GSK Posts Strong Results, Says 'Well Positioned' in Case of Pharma Tariffs
Published: April 30, 2025 by: Investopedia
Sentiment: Positive
U.S.-listed shares of GSK (GSK) are gaining in premarket trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the Trump administration imposes tariffs against the industry.
Read More
GSK: Disproportionately discounted, but earnings beat shows signs of reappraisal
Published: April 30, 2025 by: Proactive Investors
Sentiment: Positive
Shore Capital is sticking with its upbeat view on GSK PLC (LSE:GSK, NYSE:GSK), calling the stock “disproportionately discounted” after first-quarter numbers surpassed expectations and guidance was held, despite headwinds from foreign exchange and political noise around drug pricing. The key beat came on earnings, with core EPS up 5% at constant exchange rates to 44.9p, a full 10% ahead of consensus.
Read More
GSK (GSK) Q1 Earnings Surpass Estimates
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago.
Read More
GSK jumps 4% as earnings beat boosts confidence
Published: April 30, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% on Tuesday, adding £2.6 billion to its market value, after the drugmaker delivered better-than-expected first-quarter results and reiterated full-year guidance. The FTSE 100 group reported core earnings per share of 44.9p, 10% ahead of consensus, thanks to stronger operating leverage and a robust margin of 33.7%.
Read More
About GSK plc (GSK)
- IPO Date 1980-03-28
- Website https://www.gsk.com
- Industry Drug Manufacturers - General
- CEO Ms. Emma Natasha Walmsley
- Employees 68629